Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Associated Therapies: -

Clinical Trials

Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: AML

First Posted Date: 2008-08-29

Last Posted Date: 2023-03-10

Lead Sponsor: Goethe University

Target Recruit Count: 130

Registration Number: NCT00744081

Locations: 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: topotecan
Drug: pazopanib

First Posted Date: 2008-08-12

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 68

Registration Number: NCT00732420

Locations: 🇳🇱
GSK Investigational Site, Utrecht, Netherlands

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Not Applicable

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Liposomal Doxorubicin
Drug: Topotecan

First Posted Date: 2008-07-22

Last Posted Date: 2018-01-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 4

Registration Number: NCT00720096

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

Phase 1

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Topotecan
Drug: RAD001

First Posted Date: 2008-06-24

Last Posted Date: 2014-01-14

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT00703807

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Phase 1 Intrathecal Topotecan for Neoplastic Meningitis

Phase 1

Completed

Conditions: Neoplastic Meningitis

First Posted Date: 2008-05-08

Last Posted Date: 2012-05-15

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 22

Registration Number: NCT00674674

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: stealth liposomal doxorubicin
Drug: carboplatin
Drug: paclitaxel
Drug: Topotecan
Drug: Gemcitabine

First Posted Date: 2008-04-14

Last Posted Date: 2023-11-13

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 215

Registration Number: NCT00657878

Locations: 🇮🇹
Universita Cattolica del Sacro Cuore, Roma, Italy
🇮🇹
Ospedale Mazzoni, Ascoli Piceno, Italy
🇮🇹
Ospedale Senatore Antonio Perrino, Brindisi, Italy

and more 35 locations

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Phase 1

Completed

Conditions: Metastatic Solid Tumor

Interventions: Drug: Topotecan
Drug: Erlotinib

First Posted Date: 2008-02-11

Last Posted Date: 2011-08-22

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 29

Registration Number: NCT00611468

Locations: 🇺🇸
The West Clinic, Memphis, Tennessee, United States

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Phase 2

Completed

Conditions: Neuroblastoma
Medulloblastoma

Interventions: Drug: Nifurtimox
Drug: Cyclophosphamide
Drug: Topotecan

First Posted Date: 2008-01-25

Last Posted Date: 2024-08-06

Lead Sponsor: Giselle Sholler

Target Recruit Count: 112

Registration Number: NCT00601003

Locations: 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Children's Medical Center, Dallas, Texas, United States

and more 12 locations

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Phase 1

Completed

Conditions: Solid Tumors
Lymphomas

First Posted Date: 2007-11-04

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00553189

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: Topotecan
Drug: Cisplatin
Drug: Bevacizumab

First Posted Date: 2007-10-24

Last Posted Date: 2014-08-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 27

Registration Number: NCT00548418

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
The Ohio State University College of Medicine, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy